Treatment of advanced non small cell lung cancer

Journal of Thoracic Disease, 05/20/2011

Bareschino MA et al. – Erlotinib has showed to significantly improve survival in an unselected population of patients following the failure of one or two chemotherapy regimens. This review will discuss the different therapeutic options for first and second line treatment in the clinical practice.p>

Print Article Summary Cat 2 CME Report